ArticleJournal of pharmaceutical health care and sciences2025
Factors and preventive strategies for perioperative euglycemic diabetic ketoacidosis in patients with type 2 diabetes receiving sodium-glucose cotransporter 2 inhibitors: a retrospective study.
Article in Journal of pharmaceutical health care and sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Retinal Outcomes in Diabetes: Antihyperglycemic Therapy, EWDR, and Perioperative Considerations.Biomedicines · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundInvasive treatment and the associated stress are known risk factors for sodium-glucose cotransporter 2 inhibitor (SGLT2i)-induced euglycemic diabetic ketoacidosis (euDKA) development. It is recommended that SGLT2is is discontinued at least 3 days prior to a scheduled surgery. However, it is unclear whether preoperative discontinuation of SGLT2is is effective and whether other factors contribute to the development of SGLT2i-induced perioperative euDKA.
methodsWe retrospectively investigated the incidence of euDKA postoperatively up to 30 days in patients receiving SGLT2is and undergoing surgery under general anesthesia. Multivariate logistic regression analysis was performed to identify the factors affecting euDKA development.
resultsTwenty-one of 1,169 eligible patients (1.8%) developed perioperative euDKA. The incidence of perioperative euDKA in patients who discontinued SGLT2is for ≥ 3 days prior to surgery was significantly lower than that in patients who did not discontinue SGLT2is for ≥ 3 days prior to surgery (p < 0.001). The multivariate analysis showed that discontinuation of SGLT2is for ≥ 3 days prior to surgery and preoperative use of insulin and glucose infusion were significant factors that affected the development of perioperative euDKA (odds ratios = 0.047 and 0.054, p = 0.003 and 0.005, respectively).
conclusionsOur findings suggest that preoperative SGLT2i discontinuation for at least 3 days could prevent perioperative euDKA development and that preoperative insulin and glucose infusion could reduce the risk of developing euDKA, even in patients who cannot discontinue SGLT2is at least 3 days preoperatively.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.